We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Ranked Momentum Stocks to Buy for September 6th
Read MoreHide Full Article
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 6th:
Ligand Pharmaceuticals Incorporated : This biopharmaceutical company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 14.4% over the last 60 days.
Ligand Pharmaceuticals Incorporated Price and Consensus
Sesen Bio, Inc. : This late-stage clinical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 18.8% over the last 60 days.
Interface, Inc. (TILE - Free Report) : This modular flooring company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 1.4% over the last 60 days.
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Top Ranked Momentum Stocks to Buy for September 6th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 6th:
Ligand Pharmaceuticals Incorporated : This biopharmaceutical company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 14.4% over the last 60 days.
Ligand Pharmaceuticals Incorporated Price and Consensus
Ligand Pharmaceuticals Incorporated price-consensus-chart | Ligand Pharmaceuticals Incorporated Quote
Ligand’s shares gained 3% over the last one month more than S&P 500’s gain of 1.1%. The company possesses a Momentum Score of A.
Ligand Pharmaceuticals Incorporated Price
Ligand Pharmaceuticals Incorporated price | Ligand Pharmaceuticals Incorporated Quote
Sesen Bio, Inc. : This late-stage clinical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 18.8% over the last 60 days.
Eleven Biotherapeutics, Inc. Price and Consensus
Eleven Biotherapeutics, Inc. price-consensus-chart | Eleven Biotherapeutics, Inc. Quote
Sesen Bio’s shares gained 43.1% over the last one month. The company possesses a Momentum Score of B.
Eleven Biotherapeutics, Inc. Price
Eleven Biotherapeutics, Inc. price | Eleven Biotherapeutics, Inc. Quote
Interface, Inc. (TILE - Free Report) : This modular flooring company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 1.4% over the last 60 days.
Interface, Inc. Price and Consensus
Interface, Inc. price-consensus-chart | Interface, Inc. Quote
Interface’s shares gained 6.2% over the last one month. The company possesses a Momentum Score of A.
Interface, Inc. Price
Interface, Inc. price | Interface, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>